Table 1.
Summary of Phase 3 Clinical Trials for Cancer Nanomedicine Products.
| Composition | Responsible Party | Indication | NCT number | Status |
|---|---|---|---|---|
| Liposomal paclitaxel | SynCore Biotechnology Co., Ltd. | Pancreatic adenocarcinoma | NCT03126435 | Completed |
| Thermally sensitive liposomal doxorubicin | Imunon | Hepatocellular carcinoma | NCT00617981 | Completed |
| Liposomal VCL-1005 plasmid | Vical | Melanoma | NCT00395070 | Completed |
| Liposomal MUC1 antigen | EMD Serono | Non-small-cell lung cancer | NCT00409188 | Completed |
| Hafnium-oxide nanoparticle | Nanobiotix | Sarcoma | NCT02379845 | Completed |
| Hafnium-oxide nanoparticle | American Regent, Inc. | Non-small-cell lung cancer | NCT00243867 | Completed |
| Irinotecan PEG conjugate | Nektar Therapeutics | Breast cancer | NCT02915744 | Completed |
| NCT01492101 | Completed | |||
| Cisplatin micellar | Orient Europharma Co., Ltd. | Pancreatic cancer | NCT02043288 | Completed |
| Paclitaxel micellar | Nippon Kayaku Co., Ltd. | Breast cancer | NCT01644890 | Completed |